UTHR - Earnings call transcript Q3 2020 | United Therapeutics Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the United Therapeutics Corporation's Third Quarter 2020 Earnings Call. My name is Kenzie and I will be your conference operator today. [Operator Instructions] I will now turn the conference over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics.

Dewey Steadman

Good morning. to Therapeutics pleasure XXXX Third my Call. Earnings is the Corporation United Quarter It today's Dr. call on me Accompanying are Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. President our Benkowitz, and Officer; Operating Michael Mr. Chief James and and Edgemond, Financial Treasurer; our Chief Dr. Officer of Product Peterson, Vice Leigh Development. our President Remarks today our beliefs future regarding statements expectations or events. include will forward-looking representing statements and may uncertainties These cause differ to results involves risks materially. that actual

may not no additional also ir.unither.com. statements. for GAAP. risks prepared basis intended information Today's and to these Our on GAAP filings for to for Form including with on on that forward-looking measures latest available financial investigational developments on results solely prescribing these XX-K Full in most to measures the principles accordance safe and discuss found suggest with uses. or We any US release include information comparable generally Reconciliations obligation assume to were our accepted accounting products the SEC educate unapproved Today's financial directly as update are financial be effective earnings are remarks intended may remarks respect products medical our trials these clinical and remarks available are or and to serve measures progress investors can of any XX-Q or contain of to non-GAAP our the that or website. decision-making not website and other our These uncertainties. products. at are

Rothblatt of for turn Martine? activities overview third Therapeutics. Dr. I'll XXXX over and an to financial business United Now, of the call quarter the results

Martine Rothblatt

by our Dr. good of XXXX. I'm news Edgemond; all on today. be Dewey. Financial Benkowitz; quarter our everybody, call have We Thank the our Leigh for Head third and our Michael joined Good really James Chief welcome to report Development, to President, to Officer, morning, Product Peterson. you, call today and going earnings

fun So it's a to call. be going earnings very

good divide categories: news pulmonary into and pulmonary me fibrosis. two the Let hypertension

of number over treprostinil ever. the patients We medicines highest past start quarter the pulmonary had hypertension. on with Let's our

Orenitram addition solid number we've the double-digit patients year-to-year, be we Tyvaso, we've performance on on Remodulin also growth the Remodulin and further that, to with patients top even two growth solid enhanced our this launches planned had that, of And in performance. of On double-digit XXXX. expect In to seen quarter-to-quarter. number for of that's

First, due Implantable the difficulty Remunity System ever for subcutaneous important, launch therapy. of hypertension pulmonary ISR forms and new grave for delivery. launches are the to die launch pulmonary patients or These the to Remodulin Remodulin; access its intravenous the patients on having Remodulin for because patient on of most declined Indeed, Remodulin secondly, most Remodulin. product patients without form of hypertension

also our on of pulmonary progress significance great Speaking accelerating pipeline is ralinepag. of for hypertension, our

in the expect be trials enrolled by and capacity of We the X half Phase and ralinepag XXXX. enrolled to end fully both ralinepag the outcomes XXXX

FDA Let hypertension related our We pulmonary subject fibrosis. PDUFA 'XX, remain me to on April pulmonary of IPF-associated in its launch some then to to product to for the Tyvaso approval good date. schedule on news

That fibrosis associated study of for starting fibrosis pulmonary should then as to enrolled hypertension quarter this that everyone the penetrate pulmonary be expand to population. XXX-patient 'XX. in our only with quarter. next hypertension by of drugs Dreamboat this product pulmonary patients like pulmonary to are treat filing our with study treating of the 'XX. in footprint by we We pulmonary be pulmonary systemic expect our early-XXXX. XXXX patients possibly TreT XX,XXX-patient TETON pure Tyvaso FDA this Indeed, for first of We hypertension, the associated market by the contraindicated, remind end will for approved medicine expect the completely further to study with greatly XX,XXX or patients probably IND fibrosis TETON the type fibrosis I'd that launch the pulmonary leaving

core having with franchise one with of hypertension, of our then steady there leg only study. not hypertension lot see fence adjacent fibrosis and field the first in with happening other pulmonary in kind the the is by into X Group things side pulmonary a making Company camps the of completely of are market in but the of the that with expansion that you a the two leg fibrosis pulmonary fibrosis TETON pulmonary associated both historical pulmonary is So can also

our let While of things talk Phase going at also Phase I about call X.X on and I've the pipeline, been talking the me would about that X pipeline. our level are what

in to much than daily for more going continuing with of be times seeing that in IND our of Orenitram and will we in development based form form instrumental I This of once-daily patients in the will an early-XXXX, - will shortly. we're that Orenitram will So a the be Phase X, think regard begin the growth clinical currently on Orenitram. convenient three in double-digit be year-over-year

into 'XX. I level is would the the that is 'XX, Phase into in We activity designed go subcutaneous Phase exciting RemoPro. form X.X after Pump. Remunity ultimately fourth quarter of to say right plan pain-less move IND the the our is to This Another Remodulin, that X that and of in then file

the to porcine 'XX project. plan another to INDs kidney instead in Speaking This modified the as we in and specifically of 'XX, no in that is of appear filing than a for XX-gene to different to file allograft. is are recipient xenografting types common avoid designed rejection xenokidney another our IND

development of our our Benkowitz, of the file President, turn to in the other Phase With activities, X/X xenokidney to to a study and a of aspects move unique product type to clinical IND for microphone into next expect I'd directly our Michael of the 'XX. 'XX. due overview then, in operations, pipeline Michael? like program a commercialization. that And review including nature the give We to of that

Michael Benkowitz

Good Great. Thanks, everyone. morning, Martine.

the X% each We sequentially, and demand underlying revenues Tyvaso and sales XX% periodically revenue that in quarter. And distributors Happily, products. and growth is our that this On third during Order approximately revenue demand can at to our quarter, in year-over-year. by Excess when highlights occurred double-digit adjusted highlighted reflected report Martine of by As XXXX, Remodulin the third not performance growth our following year-over-year the basis, Unituxin. that revenues US pleased our we represent caution adjust said, distributors Tyvaso with we're may growing reflect year-over-year revenue QX is US in by Orenitram for stronger. our we grew you the by supported one and even growth our overall, and to in the extremely by revenues that strong reported the grew as quarter for saw of account growth Orenitram,

the some earlier in to pandemic, total during after treprostinil new First, experiencing softness COVID-related returned levels patient during starts pre-pandemic quarter. start the

noted, patient we've a Martine quarter for patients treprostinil achieved number as reached active row utilizing Second, our of This treprostinil one an products in our another all-time that the census of the fourth is products. high. record

We by record a following have last and Orenitram, label physicians the number continuing adoption of expansion this from benefiting therapy reflecting year. FREEDOM-EV increasing of patients

patients finally, We oral have commercial have utilizing more availability we of years a number of patients to medicines. benefiting record class five shy from Tyvaso of prior are Remodulin. just we And approximately had prostacyclin than the in

positively a of dose In levels addition impact our our revenues. we're in and patients highlights, time increases average to our length those of on medicines, stay seeing which both

the are products. the So momentum and we're near-term all way we our Meanwhile, our very towards launches. good with trending around very new of commercial making product pleased progress

hypertension with sales We to pulmonary out in expansion medical teams lung include following expected patients XXXX are support building the field-based to our disease our interstitial associated trial. April and nursing label INCREASE Tyvaso with

WHO in we're looking and for WHO X, is our patients Tyvaso considered and as treat physicians investigator new approved treating into prescribing launch solidifying meetings, their such Group which to seeing boards, and on currently data very advisory and product research conferences, the scientific with prescriber with our positive overwhelmingly very sick treatment compared the community and is indication engaging as upon ILD Tyvaso large We Between appropriate have one-on-one our momentum by X these presentations to its largest at armamentarium as Group upcoming started for near-term. well INCREASE The and the approval. market that PAH around these patients Tyvaso excitement we're interactions. for base those the forums products the FDA healthcare a roundly way in

new two pump launches Remodulin pump this earlier upcoming that our also FDA approved launch delays the Our the have subcu impacted was timing. are by believe, Remunity, overcome that progressing. we the the July case COVID-related we of In year,

clear sufficient commercial the Medtronic, our working we And inventory. the for available. FDA building have believe, launch. soon, continues ISR, outstanding we expect of stock, Pumps is once again Research, and the making we'll which for partner, with partner, the with finally, to centers year And be for commercially IV we are get safety Our We discussions Remunity their we this on DEKA to next a key which new ready them conditions our already PAH pump. track approval launch remain is

I'll the with Martine. So, turn back over call that, to

Martine Rothblatt

Edgemond and appropriate. Thanks so calls, Benkowitz them much, Peterson, the now amongst happy I'll to Mike direct I'm field and Dr. Mike. Operator, James as

Operator

go Instructions] Our you. line the of Hartaj Thank from Oppenheimer. Singh [Operator question ahead. Please first comes from

open. is line Your

Hartaj Singh

really really, And Great. quarter, team. you. good Thank and Martine a

So, thank you.

between PAH also occurring in to the opinion there and We're a occurring Martine, X physicians growth in Just Do trend mentioned, is of leader Tyvaso you. expect noticed we've patients be a you year-on-year overlap definite patients enthusiasm using there and as lot the ILD. quarters, seeing Tyvaso those uptick treating lot quick PAH treating Tyvaso. last you Group uptick that question Key that the few physicians Thank this growth. there? a on of over in a double-digit calls, then

Martine Rothblatt

hear morning. Excellent question to Thanks, this Hartaj. your voice good and

to Mike, that right patients I and in those best and of with PAH the the patients hypertension then managers treatment middle options treat the different physicians physicians teams would never of of he call who with on pulmonary those question different associated regional really right now seen ILD are be that that to all field sales have the of treat think, details with in this is their also treatment PAH normal addition person actually the assigning because ILD. who patient their amongst types

Hartaj's really if some color Mike best for the Mike, answers have So would question. that. could you on And provide

Michael Benkowitz

Sure. the Thanks, question. for Hartaj,

Tyvaso, they're to the patient. PAH or to answer is, or it's not when it's patient indicating prescriptions a referrals tell think for short are a question or physicians whether writing I PH-ILD submitting hard the

sort off-label group. What a are in as our a there's treating we got doctors we physicians in and group. there by you though maybe between - doctor and tell the an my other words, is if PAH are of a XX% see. ILD, differences see to terms overlap number it's that those patients account very treating those those to treating about doctors I few lot that versa. a is, community little see some of that patients you've the and remarks, mean, ILD sees if those number PAH in tell about can inverse only are of I patients do there's So, seeing PAH hard opening that patients some and I vice use in and relationship that XX% In the said ILD of of

doctors So, the are can are what we the see form writing prescriptions. referral on the that

believe see so are we to a exactly just patients, visibility tells vast doctors. are the that of new type have seen given but vast all submitted And are coming these typical or data your I sort we the would don't lot lead are PAH the again which And we majority PAH the whether me the, that know to think, they what obviously for that vast, haven't in us PH-ILD. underlying is Tyvaso PAH vast, majority prescriptions of by being of prescribers, the of

Martine Rothblatt

field drugs to Thanks XX,XXX very there this so WHO contraindicated. Group patients, quantity in bit patients substantial Hartaj, it's a are that a the of just of footnote very great add Group to pulmonary that are is, for I'd me hypertension, X response. systemic studied type That's X, patients the having this over interesting those Mike's for Mike. response much, quite little one

zero X Group are there about And medicines XX WHO, no available patients pulmonary So treat Group approved have hypertension. different upwards but patients, here of to as X X treat in to patients. many Group we those of the are field medicines there Group X as just

clearance in just finger will - unmet PDUFA date crossing we the could So we as us INCREASE that that only into INCREASE met to an all aware, approved And we trial, those endpoints. results was patients are that trial for medical you those be the the trial, the treatment patients. primary for on screaming XX,XXX it's a a cross would every April and translate on FDA great approved well the give of need. are Hartaj, secondary It treatment our clinical

be to there XX,XXX Operator, a going think to the question amount Thanks of that is excitement I physicians treat much something they again. So those please. with. tremendous so have next finally amongst patients

Operator

comes Our next from Please line Jefferies. of ahead. the go Eun question Yang with

is open. line Your

Eun Yang

you. Thank

For you on to ex-US? comment to another Tyvaso switching expect in your BREEZE? new need do PH-ILD, regulatory X Phase you to run for study indication TreT, And you. can then PH-ILD, use would similar in it you Thank filing

Martine Rothblatt

Yes. of of people Thank areas exploring Eun, for overlook. and those you, interesting kind questions that lot very a some

to need with So medical I to we're European questions. time, in At deal like those focused I'm asked a that here. approval huge schedule, decision about, you've talked because just we with patients gaining mostly XX,XXX regard point just unmet glad firm this the made this laser FDA haven't on the filing

So and to we'll is first US, as able the get consider strategy be a want what approach we we are best to kind approval here, Europe. and step-by-step to successfully of go to into the like then

The we approval I Dreamboat we used question easier this much be nebulizer, would three its on. a to also quite two, market, use feel the nebulizer most that INCREASE greater that larger because market whatever think, your powder device that times of the the Dreamboat FDA second dry for device that you people give convenience. the could TreT than maybe captured And in of insightful, Opti-Neb study is that is because device and submitted for part

Dreamboat study you So, Eun, BREEZE - file FDA we would take based of mentioned, the we that plan current XXXX in then its April April the period. to and for do did device normal the approval on as in approval - of

of the at hopefully, So can by then as the get of not 'XX, I my beginning that opening mentioned approved 'XX. in if we remarks, end very

Tyvaso. data If device have their that because, time larger don't Tyvaso, Dreamboat WHO comfortable for data, X desperation any a going Opti-Neb-based reach not taken treatment large longer, population, a some have WHO population really the for pulmonary whether in ILD the Group X of without think, device guidance is, fact, it's for of we'll that FDA. What be momentum approved is way, larger in rapidly which to is the based we immediately as making will did population. avail hypertension, the of will we should the WHO not study which would in the provide they X population. course, for study or BREEZE be would to nebulizer-based TreT the are Group easier immediately decision consequence, soon do Group I we least to be X, always data Now approve we will is be they form study to Group and have available little we filing to they and Dreamboat X in up by X for decision as the a that want themselves support at it in keep FDA. available. that X up going population just take that that you the patient up, in If the PDUFA wrap so we but or Group begin is our on think BREEZE the reason to and also X will populations date WHO the Group BREEZE which WHO feel things for population your to on the approved population, that Group the is And building that data X of very BREEZE approving the much or I for any in that

after on So we X with your will will X the be ILD for the Eun. be right population immediately question, right BREEZE data for BREEZE filing. that on Thanks completing

operator. question, Next

Operator

go ahead. Our next of line Suisse. Please question comes from Auster Credit with the Marty

open. is line Your

Martin Auster

the tenure taking you let two me ask Hey, my question. everybody. indulge Thanks again? Martine, for questions will to two-decade

Martine Rothblatt

being doctor. Auster. for Dr. for Marty and Yes, One being one

Martin Auster

you Thank kindly.

So, on. I to a things want couple up follow of

first anticipating if if would a volunteer to approved equivalents on of like that and you've side. xeno you might of to study with be TreT also organ what and the that The pass about you're Tyvaso? means on seen can what the reported First new on new supply be kind approval? think the the part you Can data talk you all you then what system that where that able you'll of And comment was be second meet done. were question TreT; was demand looks on at the kind the you healthy on in for device that

there US XX,XXX, XX,XXX like each think year. the something is in kidneys I transplanted

to big make of you to You thinking But you of I the of big very out on they list decisions opportunity I capabilities specifically. lot start more know wait probably that building DPF overall don't think about What meet is of kind could, long your know to demand? long-term know and is market when comment the picture there served. that opportunity? is the people need some expanding if and number kind picture how pulling about the get what a addressable there trigger Thanks. don't, maybe do to on and there

Martine Rothblatt

end front if about that. inventory at feel not, about could, house into Peterson, I'll if Kind Dr. the PK And for first the regard that xeno data, talk could coffee things you Okay. hours talk of Thanks, house. stuff. we could the talk in comfortable buildup if talking a about of the like the the Fascinating questions. to on at Marty. And with of over, roll least, we in question TreT coffee side But devices, PK a talk BREEZE, if you side.

Leigh Peterson

speak in. you. all you everyone. Hi, to Sure. Thank Great calling with for Yes.

that volunteers, study primary the completed we're show - know of between and to actually the and that And TreT. has that comparable objective all analysis you data right in TreT that been So, PK was now. the healthy was Tyvaso undergoing

you So I seeing mean, medications. this was least - final I appeared you will with TreT, the don't that one might early better an actually all Tyvaso to in entire two it label a I discuss with But dose might results to on like that device actually package know, seeing to We're breaths. two because bit than the study have from TreT also but Opti-Neb, your tell you. penetrate that little - as at seems the lung between consistent you output we're get open the and be

you with different need a And tiny so, And breaths breaths get and dose, dose. in, cartridge. it if takes whereas XX Tyvaso take you like the several the little - multiple just then it can breathe get to full or or you to X it full

And speaking, able can are so, lung final explain up being we But analyzed there. get I'm to very you definitely literally and that again, the do surprises that any penetration. will expect but shortly, not as data the be to we

Martine Rothblatt

much. Thanks, Thank very you Peterson. Dr.

regard So inventory, the good we're I going shape. think, to in with to be Marty,

request just launch for our we In of Head $X this week, of during at for fact, TreT the the million Manufacturing, XXXX. allocated Pat buildup inventory Poisson,

in of we regularly confident So, Connecticut, visits adequate I everything. the meet feel supply do we'll our needs. to the MannKind that he have And manufacturing plant where

have is of entire the probably objective we all at product is is one you have take-up. of commercially recall of launched from bonus proxy, companies two-year a inventory everybody's companywide based reviewing rate our which company As upon in for to the the products our how that

numbers manufacturing Poisson thing. the TreT which already in I a team, XX,XXX-plus of X as have and would expect mostly think, And times launch, year we XXXX team XX our his how as are that Dreamboat to are that inventory terms garner Marty. after sure we have launch, the Benkowitz in built accurate, your kidney inventory quite we done. always for at time we commercial xeno months to Pat manufacturing first can question, can many every amount that milestone Mike provide so actually regard of up XXXX, manufacturing So the and patients far I would for remember. then, making crush transplants and are as in that be back With a forecast There of they to so

to transplants, is XX,XXX into that, next living get up comes number get what number something category. that for kidney even you but kidney of dialysis. XXX,XXX If type reasons, like kidney is are that for you dialysis. or are And that related designate they people transplant, called in lot able something various a comes the a a need sundry not and the where And people kidney up relative transplants next waiting are up a is XXX,XXX are currently on and people then like there of to access the into

in only levels for the but It's the it So, of United medical diabetes the end-stage that's high States. United very to is one reason probably in not unmet largest not of the needs the States, unrelated disease. renal

what DPF. to which DPF into that facility, expect out ones I that So such that going cure xeno manufacturing in we transplantable that's kidney combination ideal as that and also a on renal make are the gene the an gene constructed the We've And level on product and IND knocking then of a is is is mentioned ideal in a or to XXXX And facility, the working spent I testing well-tolerated recipients. those And And unlimited order of have in good many after first of of kidneys out. why which for an in supply equivalent had cusp pathogen-free years knocked kidneys been have knocking knocked we by the out that then coming be based of the to genes have kidneys several been the the disease. ourselves people would really or clinic, file out sure results years it here. transplantation is think coming we not that Alabama. we've of which would be in end-stage

clinical DPF, the the will commercial scale operation. in into is I DPF referred DPF. scale a In couple Alabama one to trigger take terms trial bring commercial we scale when pull just on build years building to a of a The and would of

be So so as I on the going mentioned 'XX, in the with and once will know in think whether product. result clinical xenokidney first trigger beginning have the have we of successful would a in the we a successful the right the that in - time the 'XX IND call, to we with pull transplant xenokidney

And to would time trigger. be so that pull the the

We in Philadelphia. our have completely company architects bio at specialize manufacturing using already designed facility, They the type design of agro EwingCole in designs.

So, in we have a animal well vetted all in microbes whatnot experts design that's of been and populations. reviewed the and viruses by controlling

I Thanks contract sign rapidly be then brought So, to think proceed question. sometime like facility we for And the into and ready XXXX. last one construction could we're a operator, Marty. operation pretty the whole question, have with for that during time and

Operator

question last Cowen & Our Co. with the Thome line ahead. from comes Please Joseph go of

open. Your line is

Joseph Thome

question Hi the quarter. there. Thank you for taking and great my congrats on

you the built for are of launch? bit on patients change and bit a there little little comment potential anticipate as PH-ILD patients? can in well that Tyvaso up treatment patients is this expectation really it mentioned, currently given that will and Tyvaso are how indication ILD, great sort these Do for a of Thanks. you Just identified the paradigm in approval you aren't waiting there options on some that your

Martine Rothblatt

Sure.

level results which patients, expertly to speak were I those most charge the of produce at two-part in could a clinical about imminently the a you appearing study give the so we she that being INCREASE in ATS and at by ultimately like suggest publication. in with me the be because that peer-reviewed question, she reported going to given Dr. result conference, the part and first was are abstract answer the Peterson, believe ILD Let

the of Mike a how lot Peterson? your thing could it about time the And of the question. can of those part approach second thinking worked well of about who she Dr. then and to So patients. President, speak in about market more spent market, has talk our the the segmentation medical kind Benkowitz,

Leigh Peterson

sure. Yes,

this doctors quite a no if they data the population, X/X PAH, - documented did the right this nothing this So this actually to okay? up didn't or patient really right find go they was ILD heart that so until cath, And Tyvaso from population study, had they IPS, they that them, a you caths, - out. to necessarily the the pulmonary well INCREASE was know, give there if suspected And [ph] the works for now, And through even in have since patients in as plus population. hypertension procedure was So, order hypertension. did hypertension. this pulmonary heart treat medication is even discover pulmonary for group, invasive all there of because suspected didn't patients they in in why population,

to they an approved will So, they pulmonary that several times those treatment presumably performing degree relatively that treatment, now the soon. have there heard we've caths is be heart they a right see will - of hypertension, because do have

April. will of these the medical what something to of again, to be the with results to more expect identification PDUFA since also date this give do robust so Martine them. we population publication, prior the shortly, in we major about definitely publish yes, And So, very have journal a said

either definitely confidence additional they docs published - for in we'll that that have for approval likely is we've will them comfortable. certainly the population. And pulmonary - hypertension prescribe looking from even heard feel we the once gives have will that's be if for also in they this yes, or So they - waiting said this what patient that

that the I So answers question. hope

Martine Rothblatt

on some all medical we're that sales would And you Peterson. to from answer. Mike, That Dr. getting color teams? add was like of our Thanks, that great

Michael Benkowitz

with agree I everything Sure. Leigh said.

the because hypertension, obviously, But reasons think, there have I stated, the suspicion has there, think suspect the happens the invasive - symptoms which more putting physicians been, under-diagnosis is there are these typically out that the the I themselves. - pulmonary doctors the there severe also, of PH-ILD is for cath. that right an I a is pent-up lot - through think, patients There Dr. and demand. you as treatment present Peterson heart of an no is may of that as very become procedure

physicians, these hypertension is that with presentations it be population healthcare diagnose now team interactions well have a with that our our interactions and start of conferences, treatment percentages patient suggest those - patients available, boards, suspect pulmonary that medical their scientific All appropriately. of there healthcare and screen significant really advisory at to physicians

piece large prepare some the you and as disease. right in into that's get understand educate in disease But the for of leaders related as our now to key pulmonary certainly launch what out, understand field got part do we've of and spending that a these diagnosis? of medical the the right hypertension pulmonary educating the do - the lung hypertension April patient about doing and - we're PH-ILD, we're So the to to opinion teams how really interstitial are you cath has suspect, lot What - for a how go confirm on this things you arranging time heart for to then lead screen the do you community how patients, may okay, them physicians,

Martine Rothblatt

one Thanks, question Great. here. Do time Operator, for another Mike. bonus have lined there's you up? person

Operator

I do.

Please of ahead. with from Securities. Our question next the line go Liana Moussatos comes Wedbush

is line Your open.

Martine Rothblatt

excellent. That's

morning. Good Liana. Hi, Okay.

Liana Moussatos

you just this clinical to continues happen now of of and Good rates 'XX? morning. the what brief a can be do COVID think our be you. and and resolved overview us infection of affecting Thank up give and end between timing going maybe when are trials to Since and commercialization, a industry, you problem it's could has

Martine Rothblatt

of Liana, Company. risk management this many issue Financial in management as of COVID-XX XX,XXX ultimately And Edgemond. XX different that It's the Officer, group affects James has and foot group regarding one that have like Therapeutics people it questions group our a that a risk all In parts week United like of everything. and cover they Chief to Yes. meetings every we at XX, these the report how as kind involve XX, our Company, reports

could, we're James, color So, provide maybe if Liana's on those on some impact of terms for, of question of we ameliorating. our you perhaps some see in overall management we COVID-XX and getting Therapeutics based risk when from United when see group, - effects the inputs

James Edgemond

Martine. Thank voice. hear And your Yes. you, to good Liana,

it's not were the hotspots from is we well human across make up and beginning make we that up, business, specialty development to those organized of as sure and what that everybody to this all tune to product we Martine opportunities management that enrolled, effectively way the the individuals continued those stepped and trials, trials, trials pharmaceutical a risks to the to were with organization clinical capital and that or of leadership areas around talked around various importantly across globe. internally, respect distributors. and the begun as sure that internally And a impacts Unitarians, back and communicating make have really upon there the effective to patients everybody the as organization the each based internally, back call to about of impacts the be has risk speaking, for to are that And in So COVID-XX and the year may to as reopen team enrolled, to mentioned, with of through to the really manufacturing, a stepped around the the we've part understood been us patients think other we only were broadly the those that we those on in coordinating shut sure as enter country clinical to tool has we all some organization down I to have ourselves both impacts whole. as our the to but clinical

prepare Martine Unitarians continue of we again make to speaking, So broadly think, coordinated or as a From is an to for can we effort when right, things the a at execute sure sure it's I to the and understand better, large. standpoint in organization really patients all been aspects to does as that organization best we But the organization. continue need as to going to vigilant of stay the everybody will around we're we can near-term. make hope think perform for an and get

continue things on all I And better we'll as forward. we in that aspects, as to to think, to continue certainly sure conference communicate seriously is so, business educated and on doing it's various move large the multiple take the everybody make get and calls we'll public to at to in at filings continue continue something and educated whole and unfold our but questions,

to back you, Martine. So,

Martine Rothblatt

had great James. wrap on we've a the much, Thanks everybody earnings quarter. so call, To up,

we the both well key generally company. perhaps a lung of becoming interstitial the will and hypertension quarter at pivot in as fibrosis and be pulmonary solely pulmonary year, as hypertension company this a from half for to retrospect pivoted when this will time United be think company, I more being looked pulmonary point Therapeutics. a This forms a as of disease other

pulmonary pulmonary by pulmonary their is problem pivot but as their X, disease. pulmonary patients is the moving Group of worsened interstitial to see of source hypertension, primary lung interstitial WHO disease. of ultimately whom their the a this in can not is It's hypertension primary You course us hypertension into gravely problem, hypertension lung group

not pulmonary time, do have this simply large fibrosis. number study we're of we're form at a patients problem, hypertension you which interstitial whom group the for is moving if pulmonary moving first for Phase secondly, their the So, a hypertension pulmonary all, And into first will. they have lung disease, into time, patients one in not X for of

modify we diagram were you a able take other study couple capacity, lung large of actually forced words, of and diverse of fibrosis, pulmonary not slow at actually but that a as a vital subsets population. other sub-species see very patients you'll well we rate of decline INCREASE outcome look species it interstitial In disease, in see to the vital only disease. to a with pleased disease. really interstitial lung our improve the of of If all were is in the and forced the as the of And and capacity

Therapeutics. here exciting So, time United it's very at a

and we and expand strong your this And lung disease expand base very that you hope hypertension, to in footprint you and forward up. this Operator, can numbers your you people. our to for providing Look attention upcoming to you more so much seeing healthcare of conferences. and solid home interstitial logical ever from be adjacency better wrap basis pulmonary morning. from which can with healthcare always a have and time then at at of You larger that. Thank

Operator

participating United access available international using code rebroadcast for today's in you with replay dialing week Thank one will conference call. XXXXXXX. the Therapeutics dialing X-XXX-XXX-XXXX and Corporation callers be by X-XXX-XXX-XXXX A for for

United Therapeutics (UTHR) 28 Oct 202020 Q3 Earnings call transcript